{"id":791431,"date":"2024-12-02T07:34:01","date_gmt":"2024-12-02T12:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/"},"modified":"2024-12-02T07:34:01","modified_gmt":"2024-12-02T12:34:01","slug":"arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/","title":{"rendered":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences"},"content":{"rendered":"

<\/p>\n

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences<\/b><\/p>\n

PASADENA, Calif.–(BUSINESS WIRE<\/a>)–
\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:<\/p>\n

Piper Sandler 36th Annual Healthcare Conference \u2013 December 3-5, 2024<\/b><\/p>\n

\nType: Fireside Chat Presentation
\n
Date\/Time: December 3, 2024, 1:30 p.m. EST<\/p>\n

7th<\/sup> Annual Evercore ISI HealthCONx Conference \u2013 December 3-5, 2024<\/b><\/p>\n

\nType: Fireside Chat Presentation
\n
Date\/Time: December 4, 2024, 2:10 p.m. EST<\/p>\n

The APA\/JPS\/CAP\/IAP 2024 Joint Meeting \u2013 December 9-12, 2024<\/b><\/p>\n

\nTitle: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
\n
<\/b>Date\/Time: December 9, 2024, 12:00 p.m. HST
\n
Presenter: Eleonora Goldberg
\n
Session: Poster<\/p>\n

RNA at the Bench and Bedside IV \u2013 December 9-11, 2024<\/b><\/p>\n

\nTitle: Developing siRNA for Neurodegenerative Disorders
\n
<\/b>Date\/Time: December 9, 2024, 2:10 p.m. PST
\n
Presenter: Christine Esau
\n
Session: Pre-clinical RNA Therapeutics<\/p>\n

21st<\/sup> Global CVCT Forum \u2013 December 9-11, 2024<\/b><\/p>\n

\nTitle: A Randomized, Placebo-Controlled Phase 3 Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
\n
<\/b>Date\/Time: December 10, 2024, 7:30 p.m. EST
\n
Presenter: Jennifer Hellawell and Robert Rosenson
\n
Session: Attended Poster Viewing Session and Oral Presentation<\/p>\n

8th<\/sup> Complement-Based Drug Development Summit \u2013 December 10-11, 2024<\/b><\/p>\n

\nTitle: Targeting Complement C3 and Factor B with siRNA: Concept to Clinic
\n
<\/b>Date\/Time: December 11, 2024, 10:00 a.m. EST
\n
Presenter: James Hamilton
\n
Session: Advancing Complement Therapies: Pathways, Clinical Insights & Future Directions<\/p>\n

22nd<\/sup> World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) \u2013 December 12-14, 2024<\/b><\/p>\n

\nTitle: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
\n
<\/b>Date\/Time: December 13, 2024, 7:30-9:00 a.m. PST
\n
Presenter: Nick Leeper and Ira Goldberg
\n
Session: Poster and Abstract Oral Presentation Session<\/p>\n

\nPresentation materials may be accessed on the Events and Presentations<\/a> page under the Investors section of the Arrowhead website.<\/p>\n

About Arrowhead Pharmaceuticals<\/b><\/p>\n

\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead\u2019s RNAi-based therapeutics leverage this natural pathway of gene silencing.<\/p>\n

\nFor more information, please visit www.arrowheadpharma.com<\/a>, or follow us on X (formerly Twitter) at @ArrowheadPharma<\/a>, LinkedIn<\/a>, Facebook<\/a>, and Instagram<\/a>. To be added to the Company’s email list and receive news directly, please visit http:\/\/ir.arrowheadpharma.com\/email-alerts<\/a>.<\/p>\n

Safe Harbor Statement under the Private Securities Litigation Reform Act:<\/b><\/p>\n

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201chope,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201ctarget,\u201d \u201cforecast\u201d or \u201ccontinue\u201d or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and\/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.<\/i><\/p>\n

Source: <\/b>Arrowhead Pharmaceuticals, Inc.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20241202655432\/en\/<\/a><\/span><\/p>\n

\nArrowhead Pharmaceuticals, Inc.
\n
Vince Anzalone, CFA
\n
626-304-3400
\n
ir@arrowheadpharma.com<\/a><\/p>\n

Investors:
\n<\/b>
LifeSci Advisors, LLC
\n
Brian Ritchie
\n
<\/span>212-915-2578
\n
britchie@lifesciadvisors.com<\/a><\/p>\n

Media:
\n<\/b>
LifeSci Communications, LLC
\n
Kendy Guarinoni, Ph.D.
\n
724-910-9389
\n
kguarinoni@lifescicomms.com<\/a><\/p>\n

KEYWORDS:<\/b> Hawaii Florida District of Columbia New York California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Diabetes Genetics Clinical Trials Pharmaceutical Cardiology Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 4, 2024, 2:10 p.m. EST The APA\/JPS\/CAP\/IAP 2024 Joint Meeting \u2013 December 9-12, 2024 Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) Date\/Time: December 9, 2024, 12:00 p.m. HST Presenter: … <\/p>\n

Continue reading “Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791431","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 4, 2024, 2:10 p.m. EST The APA\/JPS\/CAP\/IAP 2024 Joint Meeting \u2013 December 9-12, 2024 Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) Date\/Time: December 9, 2024, 12:00 p.m. HST Presenter: … Continue reading "Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T12:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences\",\"datePublished\":\"2024-12-02T12:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/\"},\"wordCount\":949,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/\",\"name\":\"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2024-12-02T12:34:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk","og_description":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference \u2013 December 3-5, 2024 Type: Fireside Chat Presentation Date\/Time: December 4, 2024, 2:10 p.m. EST The APA\/JPS\/CAP\/IAP 2024 Joint Meeting \u2013 December 9-12, 2024 Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) Date\/Time: December 9, 2024, 12:00 p.m. HST Presenter: … Continue reading \"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-02T12:34:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences","datePublished":"2024-12-02T12:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/"},"wordCount":949,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/","name":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en","datePublished":"2024-12-02T12:34:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241202655432r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2024-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791431"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791431\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}